Long-running scheme misled investors on stock markups, fees
Court orders prison, restitution for misappropriating investors' money
Company, executives agree to settle allegations, pay US$41 million
Increase in claimed class-action damages points to larger settlements
Execs falsely inflated firm's revenues to enable acquisition, regulator charges
Ex-CEO misled investors over regulatory approval for new drugs
U.S. authorities allege biostatistician traded on cancer drug data
Regulator settled with Rio Tinto, former CEO in 2023
SEC, DoJ charge six in market manipulation, insider trading schemes
CFTC pays second award of 2025, SEC's payouts out of the spotlight